Trial Profile
A Pragmatic Randomized Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes Patients (DECIDE Study)
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 07 Dec 2023
Price :
$35
*
At a glance
- Drugs Dapagliflozin (Primary) ; Acarbose; Metformin; Nateglinide; Pioglitazone; Repaglinide
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms DECIDE
- Sponsors AstraZeneca
- 04 Dec 2023 Planned End Date changed from 30 Jun 2023 to 31 Jul 2024.
- 04 Dec 2023 Planned primary completion date changed from 30 Jun 2023 to 31 Jul 2024.
- 09 May 2023 Planned End Date changed from 30 Jun 2022 to 30 Jun 2023.